Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Tyra Biosciences Inc.

In a report released today, Eliana Merle from Barclays maintained a Buy rating on Tyra Bioscience, with a price target of $59.00. Merle covers the ...

Tyra Bioscience (TYRA) Gets a Buy from Barclays

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tyra Bioscience (TYRA – Research Report) and Veeva S...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TYRA	$36.69	-1.19%	1.01M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TYRA	$36.69	-1.2%	1.01M
3
4
5
6

TYRA

TYRA

Get Tyra Biosciences Inc. Data in Excel

Get Tyra Biosciences Inc. Data in Excel